<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4006">
  <stage>Registered</stage>
  <submitdate>9/07/2013</submitdate>
  <approvaldate>9/07/2013</approvaldate>
  <nctid>NCT01897779</nctid>
  <trial_identification>
    <studytitle>Safety, Tolerability, Pharmacokinetics of Intravenous RPX2014 and RPX7009 in Healthy Adult Subjects</studytitle>
    <scientifictitle>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous RPX2014 and RPX7009 Alone and in Combination in Healthy Adult Subjects</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Rempex 501</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy Volunteers</healthcondition>
    <healthcondition>Bacterial Infections</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - RPX7009
Treatment: drugs - RPX2014
Treatment: drugs - Placebo
Treatment: drugs - Combination RPX7009 and RPX2014

Experimental: Single and multiple dose of RPX7009 - Single and multiple dose of RPX7009

Experimental: Single and multiple dose of RPX2014 - Single and multiple dose of RPX2014

Placebo Comparator: Normal Saline - Single and multiple dose of normal saline

Experimental: Combination RPX7009 and RPX2014 - Single and Multiple dose of Combination RPX7009 and RPX2014


Treatment: drugs: RPX7009
Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.

Treatment: drugs: RPX2014
Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.

Treatment: drugs: Placebo
Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.

Treatment: drugs: Combination RPX7009 and RPX2014
Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety from baseline through the end of the study - Number of patients with adverse events; assessed by patient reporting, collection of vital signs, ECGs and absolute values and changes over time of hematology, chemistry and urinalysis.</outcome>
      <timepoint>Study Day 1 to Day 14</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Composite of PK parameters RPX7009, RPX2014, combination of RPX7009 and RPX2014 &amp; placebo following single and multiple dose administration. - Plasma AUC0-t, AUC0-inf, Cmax, and Tmax.</outcome>
      <timepoint>Study Day1 to Day 14</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Healthy adult males and females, 18 to 55 years of age (inclusive) at the time of
             screening.

          2. Body mass index (BMI) = 18.5 and = 29.9 (kg/m2) and weight between 55.0 and 100.0 kg
             (inclusive).

          3. Medically healthy with clinically insignificant screening results (e.g., laboratory
             profiles, medical histories, ECGs, physical examination) as deemed by the PI.

          4. Non-tobacco/nicotine-containing product users for a minimum of Dose Study 6 months
             prior to Day 1.

          5. Voluntarily consent to participate in the study.

          6. Sexually abstinent or agree to use two approved methods of contraception.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological,
             or psychiatric disease.

          2. Positive urine drug/alcohol testing at screening or check-in (Day -1).

          3. Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen
             (HBsAg), or hepatitis C antibodies (HCV).

          4. History or presence of alcoholism or drug abuse within the 2 years prior to Day 1.

          5. Use of any over-the-counter (OTC) medication, including herbal products and vitamins,
             within the 7 days prior to Day 1. Up to 2 grams per day of acetaminophen is allowed
             for acute events at the discretion of the PI.

          6. Blood donation or significant blood loss (i.e., &gt; 500 mL) within 56 days prior to Day
             1.

          7. Plasma donation within 7 days prior to Day 1.

          8. Participation in another investigational clinical trial within 30 days prior to Day 1.

          9. Subjects who have any abnormalities on laboratory values at screening or check-in (Day
             -1).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>94</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>CMAX - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>RPX7009 (beta-lactamase inhibitor) is being studied in combination with a carbapenem
      (RPX2014) to treat bacterial infections, including those due to multi-drug resistant
      bacteria.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01897779</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jeffery Loutit</name>
      <address>Sponsor GmbH</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>